Every Form 4 that Neogen Corp (NEOG) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow NEOG and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NEOG filings page.
NEOG CEO and director Mikheal Nassif reported a purchase of 505 common shares on October 9, 2026, at $11.95 per share. The shares were held indirectly by his son, and Nassif disclaimed beneficial ownership. The reported post-transaction position for the indirect holding was 1,579 shares. No Rule 10b5-1 plan is reported.
Neogen Corp. (NEOG) director Catherine E. Woteki received awards on October 1, 2026, consisting of options covering 20,558 common shares at a $12.24 exercise price and 9,804 restricted stock units. The options and RSUs vest in equal annual installments on each of the first three anniversary dates of the grants. Her reported restricted stock unit holdings after the award were 28,921.
NEOGEN CORP (NEOG) director Andrea F. Wainer received awards on October 1, 2026, including options covering 20,558 common shares at an exercise price of $12.24 per share, and 9,804 restricted stock units. The options expire October 1, 2036. Both awards vest in equal annual installments on each of the first three anniversary dates of the grants. Her reported post-transaction positions were 20,558 options and 11,834 restricted stock units.
Neogen Corp. (NEOG) director Rafael A. Rodriguez received an award of rights to buy 20,558 common shares at an exercise price of $12.24, along with 9,804 restricted stock units, on October 1, 2026. The reported holdings after the awards were 20,558 rights to buy common stock and 30,625 restricted stock units. Both awards vest in equal annual installments on each of the first three anniversary dates of the grants; the rights to buy common stock expire October 1, 2036.
Avi Pelossof, a director of NEOGEN Corp., received an award of options covering 20,558 common shares at a $12.24 exercise price and 9,804 restricted stock units on October 1, 2026. His reported direct positions after the awards were 20,558 options and 9,804 restricted stock units. Both awards vest in equal annual installments on each of the first three grant anniversaries; the options expire October 1, 2036.
NEOGEN Corp (NEOG) director Aashima Gupta received two awards on October 1, 2026: 20,558 options to buy common stock, with a $12.24 exercise price, and 9,804 restricted stock units. Both awards vest in equal annual installments on each of the first three grant anniversaries. The options expire October 1, 2036. Following the RSU award, her reported shares were 37,594.
Neogen Corp. (NEOG) director Ronald D. Green reported equity awards dated October 1, 2026: 20,558 options to buy common stock and 9,804 restricted stock units (RSUs). The options carry a $12.24 exercise price and expire October 1, 2036. Green's reported direct RSU holdings after the award were 28,458. No Rule 10b5-1 plan is reported.
NEOGEN CORP (NEOG) director Jeffrey D. Capello was granted 20,558 options to buy common stock and 9,804 restricted stock units on October 1, 2026. The options have an exercise price of $12.24 per share and expire October 1, 2036. The reported post-transaction position was 20,558 options and 42,306 shares, respectively. Both award types vest in equal annual installments on each of the first three anniversary dates of the grants.
NEOG director James C. Borel received grants of 20,558 options to buy common stock and 9,804 restricted stock units on October 1, 2026. Both award types vest in equal annual installments on each of the first three grant anniversaries. The options have a $12.24 exercise price and expire October 1, 2036.
NEOGEN CORP (NEOG) reported an insider equity event involving Chief Accounting Officer John Patrick Moylan. On August 19, 2026, restricted stock units vested, and 2,365 shares of common stock underlying those RSUs were disposed of through share withholding to cover tax liabilities. Following this tax-withholding disposition, Moylan directly held 29,331 shares of NEOG common stock.
NEOGEN CORP (NEOG) reported an insider equity transaction by CEO and director Mikheal Nassif. On August 19, 2026, restricted stock units vested on the anniversary of the grant date, and 20,397 shares of common stock were disposed of through share withholding to cover tax liabilities on the vested RSUs. Following this tax-withholding disposition, Nassif’s directly held common stock position is reported as 25,655 shares.
NEOGEN CORP’s Chief Accounting Officer, John Patrick Moylan, received new equity awards on August 14, 2026. He was granted options to buy 18,693 shares of common stock at an exercise price of $11.65 per share, expiring August 14, 2036, and 8,584 restricted stock units. Both the options and RSUs vest in equal annual installments on each of the first three anniversary dates of the grants. Following these awards, he directly holds 18,693 derivative option shares and 32,155 non-derivative shares/RSUs. The filing indicates these awards were not made under a Rule 10b5-1 trading plan.
Neogen Corp reported equity compensation awards to Senior Vice President Tamara A. Ranalli. She received options to acquire 130,851 shares of common stock at an exercise price of $11.65 per share, expiring on August 14, 2036. According to the footnote, these options vest in equal annual installments on each of the first three anniversaries of the grant date.
Ranalli also received a grant of 25,751 shares of common stock, described as PSUs, at a reference price of $11.65 per share. The PSUs vest in total at the end of the three-year anniversary date of the grant. All reported holdings following these awards are shown as directly owned.
NEOGEN CORP reported equity compensation awards to Chief Legal Officer Stacey Jennifer Evans on August 14, 2026. She received options to acquire 196,276 shares of common stock at an exercise price of $11.65 per share, expiring August 14, 2036, vesting in equal installments over three years. She also received 38,627 performance stock units, which vest in total at the end of a three-year period, with both positions reported as directly owned after the grants.
NEOGEN CORP reported equity awards to its CFO, Richard Bryan Riggsbee, on 2026-08-14. He received an option grant covering 261,702 shares of Common Stock at an exercise price of $11.65 per share, expiring on 2036-08-14. According to the disclosure, these options vest in equal annual installments over the first three anniversaries of the grant date.
On the same date, he also received a grant of 51,502 shares of Common Stock, referenced as PSUs, at a stated value of $11.65 per share. The PSUs vest in total at the end of the three-year anniversary of the grant date. Both positions are reported as directly owned following the transactions.
NEOGEN CORP CEO Mikheal Nassif reported two equity awards on August 14, 2026. He received options for 719,679 shares of common stock at an exercise price of $11.65 per share, expiring on August 14, 2036; these options vest in equal annual installments over three years. He also received 141,631 performance stock units (PSUs), which vest in total on the three-year anniversary of the grant. Following these awards, reported direct holdings are 141,631 common shares and 719,679 option-based rights.
NEOGEN CORP CEO Mikheal Nassif reported an indirect purchase of 370 shares of Common Stock on 2026-08-04 at $11.81 per share. The shares are held by his son, resulting in reported indirect holdings of 1,074 shares. Nassif disclaims beneficial ownership of these securities.
NEOGEN CORP Chief Accounting Officer handles RSU tax withholding. On June 3, 2026, restricted stock units vested on the anniversary of the grant date. To cover taxes on the vested shares, 2,553 shares were withheld at an indicated value of $8.75 per share. After this non‑market, tax-withholding disposition, John Patrick Moylan directly holds 23,571 shares of NEOGEN stock.
NEOGEN CORP’s former Chief Legal Officer, Amy M. Rocklin, exercised equity awards and settled related taxes. She converted 35,183 Restricted Stock Units into 35,183 shares of Common Stock at $9.29 per share.
To cover tax obligations, 10,241 shares of Common Stock were delivered back at $9.29 per share in a tax-withholding disposition, a non-market transaction. After these events, she directly holds 82,182 shares of NEOGEN CORP Common Stock.
NEOGEN CORP Chief Accounting Officer John Patrick Moylan reported routine equity compensation activity involving company stock. On May 4, 2026, he exercised 4,558 Restricted Stock Units into common shares at $9.53 per share. To cover related tax obligations, 1,568 common shares were disposed of as a tax-withholding transaction, not an open-market sale. Following these transactions, Moylan directly holds 17,337 shares of NEOGEN common stock.
NEOGEN CORP Chief Legal Officer Stacey Jennifer Evans reported equity awards of common stock and stock options. She received 39,349 shares of Common Stock on May 1, 2026, valued at $9.53 per share, and now holds that amount directly.
On the same date she was granted 89,520 options to buy Common Stock at an exercise price of $9.53 per share, expiring on May 1, 2036. According to the footnote, these options and related RSUs vest in equal annual installments over three years, making this a multi-year compensation grant rather than an open-market trade.
Neogen Corp’s CEO, Nassif Mikheal, reported an indirect open‑market purchase of company stock associated with his son. On February 17, 2026, 23 shares of Neogen common stock were bought at $10.94 per share. Following this trade, 704 shares are reported as indirectly owned "by son." A footnote states that Mikheal disclaims beneficial ownership of these securities, meaning he does not concede that he is their beneficial owner for regulatory or any other purpose.
Neogen Corporation filed a Form 4 detailing small stock purchases made in an account held by the CEO’s son. On 01/26/2026, the son purchased 25 shares of common stock at $9.855 per share, and on 02/02/2026, 24 shares at $9.9997 per share. After these trades, that account held 681 shares. The filing states that CEO Nassif Mikheal reports these holdings indirectly and expressly disclaims beneficial ownership of these securities.
Neogen Corporation reported that a senior vice president received new equity awards on 01/07/2026. The officer was granted 261,210 stock options with a conversion price of $7.38 per share, exercisable until 01/07/2036, covering 261,210 shares of common stock.
In addition, the officer acquired 50,813 shares of common stock linked to options and RSUs and another 50,813 shares tied to PSUs, both at a reference price of $7.38 per share. The options and RSUs vest in three equal annual installments, while the PSUs vest in full at the end of the three-year anniversary of the grant.
Neogen Corporation Senior Vice President Tamara A. Ranalli reported new equity awards. On January 7, 2026, she was granted 130,605 options to acquire Neogen common stock at an exercise price of $7.38 per share, leaving her with 130,605 derivative securities beneficially owned directly. The same day she also acquired 50,813 shares of common stock at a stated price of $7.38 per share, bringing her directly held common stock to 50,813 shares. According to the filing, the options and restricted stock units vest in three equal annual installments on each of the first three anniversaries of the grant date.
Neogen Corporation insider reporting shows an indirect purchase of company stock linked to its CEO. On January 16, 2026, an account held by the CEO’s son bought 137 Common Shares of Neogen at $9.3349 per share. After this trade, that account held 632 Common Shares in total. The transaction is reported as indirect ownership "By son", and the reporting person, CEO and director Nassif Mikheal, explicitly disclaims beneficial ownership of these securities.
Neogen Corp (NEOG) reported an insider transaction on a Form 4. A company insider who is both a Director and CEO reported an open‑market purchase (code P) of 177 common shares at $6.25 on 11/03/2025.
Following this transaction, the filing lists 495 shares beneficially owned, reported as Indirect (I) by son. The filing includes a standard disclaimer that the reporting person disclaims beneficial ownership of these indirectly held securities.
Neogen (NEOG) reported an insider equity transaction by its CFO. On 11/03/2025, the officer acquired 178,855 shares of common stock at a stated price of $6.29, bringing directly held common shares to 178,855. The filing also shows a grant of stock options for 459,713 shares with an exercise price of $6.29.
According to the footnotes, the options vest in equal annual installments over three years from the grant date, while the performance stock units vest in total at the end of the three-year anniversary of the grant.
Neogen Corp (NEOG) reported a director’s equity transaction. On 10/27/2025, 1,777 restricted stock units (RSUs) vested and were settled into an equal number of common shares via transaction code M. The non-derivative table shows 1,777 shares acquired at a listed price of $6.19. Following the transaction, the reporting person beneficially owned 96,347 shares directly. Remarks confirm each RSU equals one share and that the RSUs vested and were settled on the same date.
NEOGEN Corp (NEOG) insider update: A company director reported the vesting and settlement of 1,777 restricted stock units into an equal number of common shares on 10/27/2025. The filing lists a reported price of $6.19 for the transaction. Following this event, the director directly beneficially owns 32,502 shares of NEOG common stock.
Neogen Corporation reported an insider transaction on Form 4 for a director. On 10/27/2025, 1,777 shares of common stock were acquired upon settlement of restricted stock units (Transaction Code: M) at a stated price of $6.19 per share. Following the transaction, the director beneficially owned 18,654 shares, held directly.
The filing notes each RSU equals one share of common stock and that these RSUs vested and were settled on 10/27/2025.
Neogen Corporation (NEOG) reported an insider equity change. A director acquired 1,777 shares of common stock on October 27, 2025 through the vesting and settlement of restricted stock units (transaction code M), listed at $6.19 per share. Following this transaction, the director’s beneficial ownership stands at 27,790 shares, held directly.
Each RSU converted into one share of common stock at vesting, resulting in a one-for-one issuance without a market purchase.
Neogen Corporation (NEOG) reported an insider equity change. A director acquired 1,777 shares of common stock on 10/27/2025 upon the settlement of restricted stock units, recorded at $6.19 per share under code M. Following the transaction, the director directly beneficially owned 20,821 shares.
Each RSU was the economic equivalent of one common share and vested on 10/27/2025, settling into an equal number of shares of common stock.
NEOGEN (NEOG) reported a routine insider equity event. A director acquired 1,777 shares of common stock on 10/27/2025 through the vesting and settlement of restricted stock units, reflected with transaction code M. The filing lists a price of $6.19 associated with the conversion. Following this transaction, the director beneficially owns 43,347 shares, held directly.
Neogen Corp (NEOG) disclosed a director transaction on a Form 4. On October 27, 2025, 1,777 restricted stock units vested and were settled for an equal number of common shares at a labeled price of $6.19 per share (Transaction Code M).
After the settlement, the director beneficially owned 19,117 shares, held directly. The filing notes that each RSU was the economic equivalent of one share of common stock, and these RSUs vested and were settled for the same number of shares on the stated date.
Neogen Corp (NEOG) insider activity: The company’s Chief Legal Officer reported the vesting and settlement of 9,474 restricted stock units into common stock on 10/27/2025, shown with transaction code M at a stated price of $6.19. A follow-on entry with code F reflects the disposition of 2,085 shares, typically for tax withholding, also at $6.19. After these transactions, the officer directly owned 57,240 shares.
The remarks clarify that each RSU equals one share of common stock and that the RSUs vested on October 27, 2025.
NEOGEN (NEOG) reported an insider transaction by its Chief Financial Officer. On October 27, 2025, 15,504 restricted stock units vested and were settled into the same number of common shares (code M) at $6.19. To cover taxes, 4,261 shares were withheld (code F) at $6.19. After these transactions, the officer directly owned 81,024 shares. Each RSU is equivalent to one share of common stock.
Neogen (NEOG) reported an insider equity event. On October 27, 2025, a former COO had 15,504 restricted stock units vest and convert to common stock (code M at $6.19 per unit). To cover taxes, 3,481 shares were withheld (code F at $6.19 per share). After these transactions, the insider beneficially owned 100,881 shares, held directly.
Each RSU was the economic equivalent of one share of common stock.
Neogen Corp (NEOG) insider filing: An officer (Former CEO) reported RSU vesting and related share movements. On October 27, 2025, 38,759 restricted stock units vested and were settled into an equal number of common shares at $6.19 per share (code M). A separate transaction disposed of 8,527 shares at $6.19 (code F).
Following these transactions, the reporting person beneficially owned 363,081 shares, held directly.
Neogen Corp (NEOG) director reported an RSU vesting on October 27, 2025: 3,553 shares of common stock were acquired via a code “M” conversion at $6.07 per share. Following the settlement, the reporting person beneficially owns 47,913 shares, held directly.
Each RSU equaled one share, and the RSUs vested and were settled for an equal number of shares on October 27, 2025.
Neogen Corp (NEOG) reported a routine insider equity event. A director converted restricted stock units into common shares on 10/27/2025 (Transaction Code M). 2,025 shares of common stock were acquired at $6.19 per share upon RSU vesting and settlement. Following the transaction, the director beneficially owns 30,725 shares directly. The filing also lists 4,050 derivative securities (RSUs) beneficially owned after the reported transaction.
Neogen Corp (NEOG) reported an insider equity change by a director. On October 27, 2025, 2,025 restricted stock units vested and were settled into 2,025 shares of common stock (transaction code M) at a listed price of $6.19 per share. Following this settlement, the reporting person directly owned 94,570 shares.
Neogen Corporation (NEOG) reported an insider transaction by a director. On 10/24/2025, the director acquired 19,386 shares of common stock at a $6.19 price and now holds 19,386 shares directly.
The filing also reports a grant of 49,929 stock options with a $6.19 exercise price, expiring on 10/24/2035. The options and RSUs vest in equal annual installments on each of the first three anniversary dates of the grants.
Neogen Corp (NEOG) Form 4: A company director reported transactions dated 10/23/2025. The filer acquired 19,769 shares of common stock at $6.07, bringing directly held shares to 35,084 after the transaction. The filing indicates direct ownership.
The director was also awarded options covering 50,814 shares at an exercise price of $6.07, expiring 10/23/2035. According to the footnote, options and RSUs vest in equal annual installments on each of the first three anniversaries of the grant.
Neogen Corp (NEOG) — Form 4 insider report: A company director reported acquiring 19,769 shares of common stock on 10/23/2025 at $6.07 per share, bringing direct beneficial ownership to 19,769 shares. The filer also received a grant of options for 50,814 shares at a $6.07 exercise price, expiring 10/23/2035. Per the footnote, these awards vest in equal annual installments on each of the first three anniversaries of the grant date.
Neogen (NEOG) filed a Form 4 reporting director equity awards. On 10/23/2025, the reporting person acquired 19,769 shares of common stock at $6.07. Following this, directly held common stock totaled 36,788 shares.
The filing also reports 50,814 stock options granted at an exercise price of $6.07, expiring on 10/23/2035, with 50,814 derivative securities beneficially owned after the transaction. Per the footnote, options and RSUs vest in equal annual installments on each of the first three anniversary dates of the grants.
Neogen Corporation (NEOG) director reported equity grants. On 10/23/2025, the insider acquired 19,769 shares of common stock at $6.07 per share, bringing direct beneficial ownership to 43,757 shares. The filer also reported a grant of options to buy 50,814 shares at an exercise price of $6.07, expiring on 10/23/2035. According to the footnote, the options and RSUs vest in equal annual installments on each of the first three anniversaries of the grant date.
Neogen Corp (NEOG) reported an insider equity transaction. A director acquired 19,769 shares of common stock at $6.07 on 10/23/2025 (Transaction Code A). Following this, the director beneficially owned 34,621 common shares directly.
The filing also reports a grant of options to purchase 50,814 shares at an exercise price of $6.07, expiring on 10/23/2035. After the transactions, the director held 50,814 options. The options and RSUs vest in equal annual installments on each of the first three anniversary dates of the grants.
Neogen Corp (NEOG) — Form 4 insider report: A director reported an award on 10/23/2025. The filing shows 19,769 shares of common stock acquired (Code A) at $6.07, bringing direct beneficial ownership to 48,469 shares. The director was also granted options to purchase 50,814 shares at an exercise price of $6.07, expiring 10/23/2035. A footnote states the options and RSUs vest in equal annual installments on each of the first three anniversary dates of the grants.
Neogen Corp (NEOG) — Form 4 insider activity: A director reported awards dated 10/23/2025. The filing shows an acquisition of 19,769 shares of common stock and a grant of options covering 50,814 shares with a $6.07 exercise price, expiring on 10/23/2035. The form lists 19,769 common shares and 50,814 derivative securities beneficially owned following the transactions, all held directly. Both the options and RSUs vest in equal annual installments on each of the first three anniversaries of the grants.